Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies

Steenbergen, Judith N.; Mohr, John; Thorne, Grace M.

doi:10.1093/jac/dkp346

Cited by 88 publications

(51 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether even higher, off-label daptomycin doses would increase efficacy in the treatment of VRE bacteremia, without increasing toxicity, also remains to be explored. Similarly, the effect of proposed strategies of combination treatment with daptomycin and ampicillin (31) or rifampin (34) could not be assessed adequately from these data.…”

Section: Discussionmentioning

confidence: 98%

Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia

Balli

Venetis

Miyakis

2014

Antimicrob Agents Chemother

138

View full text Add to dashboard Cite

cLimited therapeutic options exist for the treatment of vancomycin-resistant Enterococcus (VRE) bacteremia; the most commonly used are daptomycin and linezolid. We attempted a systematic review and meta-analysis of the comparative efficacy of those two agents. Studies comparing daptomycin to linezolid treatment for VRE bacteremia, published until August 2012, were identified from the MEDLINE, EMBASE, CENTRAL, ISI Web of Science, and SCOPUS databases. All comparative studies on patients older than 18 years of age that provided mortality data were considered eligible for this systematic review and meta-analysis. ⌻he primary outcome of the meta-analysis was 30-day all-cause mortality. Ten retrospective studies including 967 patients were identified. Patients treated with daptomycin had significantly higher 30-day all-cause mortality (odds ratio [OR], 1.61; 95% confidence interval [CI], 1.08 to 2.40) and infection-related mortality (OR, 3.61; 95% CI, 1.42 to 9.20) rates than patients treated with linezolid. When data from all 10 studies were combined, overall mortality was also significantly increased among patients treated with daptomycin (OR, 1.41; 95% CI, 1.06 to 1.89). These findings were confirmed when odds ratios adjusted for potential confounders were pooled. Relapse rates among patients treated with daptomycin were also higher (OR, 2.51; 95% CI, 0.94 to 6.72), although this difference did not reach statistical significance. Adverse event rates were not significantly different between the two groups. Notwithstanding the absence of randomized prospective data, available evidence suggests that mortality rates may be higher with daptomycin than with linezolid among patients treated for VRE bacteremia. E nterococci are the third most common cause of health careassociated bloodstream infections (BSIs) (1). Vancomycin is the first-line treatment of BSIs caused by ampicillin-resistant enterococci; however vancomycin-resistant enterococci (VRE) nowadays account for approximately one-third of the enterococcal health care-associated infections in the United States (2) and for more than 20% of such infections in some European countries (3). Mortality rates in patients with VRE BSIs range between 20 and 46% (4-6). Patients with BSI due to VRE are 2.5 times more likely to die than patients with BSI due to vancomycin-susceptible strains (7).Treatment of VRE BSIs is particularly challenging. Strains causing such infections are usually resistant to ampicillin (8), and therapeutic options include linezolid, daptomycin, quinupristindalfopristin, tigecycline, teicoplanin, and telavancin (for which limited clinical data are available). Teicoplanin is not available in the United States and can only be used for some VRE infections (i.e., strains with the VanB [vancomycin-resistant, teicoplaninsusceptible] phenotype and the rare species Enterococcus gallinarum and E. casseliflavus). Tigecycline does not achieve high serum concentrations and has not been approved for treatment of bacteremias (9). Use of quinupristin-dalfopristin (ef...

show abstract

Section: Discussionmentioning

confidence: 98%

Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia

Balli

Venetis

Miyakis

2014

Antimicrob Agents Chemother

138

View full text Add to dashboard Cite

show abstract

“…Several in vitro and animal infection models have shown additive or synergistic effects with DAP combination therapy (29,42,44). Previous work has examined the effect of combination exposures on the emergence of DAP resistance, although these studies are often limited by a number of factors, including short exposure duration, use of static antibiotic concentrations, testing of reference strains rather than clinical isolates, and the small number of combinations examined (4,20,35,38).…”

mentioning

confidence: 99%

“…Eight antimicrobials that have been used therapeutically in combination with DAP were selected (29,42,44). In addition to measuring changes in the DAP MIC, strains selected under these antimicrobial combinations were examined for phenotypic changes associated with DAP resistance, including changes to cell wall thickness (CWT) and cell membrane physiology.…”

mentioning

confidence: 99%

Altering the Proclivity towards Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus Using Combinations with Other Antibiotics

Berti

Wergin

Girdaukas

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

ABSTRACTDaptomycin (DAP) is increasingly used as a part of combination therapy, particularly in complex methicillin-resistantStaphylococcus aureus(MRSA) infections. While multiple studies have reported the potential for synergy between DAP and adjunctive anti-infectives, few have examined the influence of adjunctive therapy on the emergence of DAP resistance. This study examined eight adjunctive antimicrobial combinations with DAPin vitroand the emergence of DAP resistance over time (up to 4 weeks) using clinical isolates of DAP-susceptible MRSA (MIC, 0.5 μg/ml) in which DAP resistance subsequently developed during patient therapy (MIC, 3 μg/ml). In addition to DAP susceptibility testing, selected strains were examined for phenotypic changes associated with DAP resistance, including changes to cell wall thickness (CWT) and cell membrane alterations. The addition of either oxacillin or clarithromycin in medium containing DAP significantly inhibited the development of DAP resistance through the entirety of the 4-week exposure (10- to 32-fold MIC reduction from that of DAP alone). Combinations with rifampin or fosfomycin were effective in delaying the emergence of DAP resistance through the end of week one only (week one MIC, 0.5 μg/ml; week four MIC, 24 μg/ml). Cell wall thickening was observed for all antibiotic combinations regardless of their effect on the DAP MIC (14 to 70% increase in CWT), while changes in cell membrane fluidity were variable and treatment dependent. DAP showed reduced activity against strains with DAP MICs of 1 to 12 μg/ml, but cell membrane integrity was still disrupted at concentrations achieved with doses greater than 10 mg/kg of body weight. The emergence of DAP resistance in MRSA is strongly influenced by the presence of subinhibitory concentrations of adjunctive antimicrobials. These data suggest that combining DAP with oxacillin or clarithromycin may delay the development of DAP resistance in cases requiring prolonged antibiotic therapy.

show abstract

“…Interaction of the combination of daptomycin with other antibiotics and its clinical benefits have been investigated for years 15 . Rifampicin effects by inhibiting DNA-dependent RNA polymerase of bacteria.…”

Section: Figure 2 Mic Distributions Of Antibiotics Tested Against Nomentioning

confidence: 99%

In-vitro activities of daptomycin in combination with rifampicin and gentamicin against VRE strains.

Aktaş¹,

Derbentli²

2016

Kafkas J Med Sci

View full text Add to dashboard Cite

AIM: In-vitro activity of daptomycin in combination with rifampicin and gentamicin, was assessed against vancomycin-resistant enterococci (VRE) with both high-level aminoglycoside resistance (HLAR) and non-HLAR. METHODS: Kafkas J Med Sci 2016; 6(3):162-168 • doi: 10.5505/kjms.2016.29974 ÖZET %34,8 (8/23) ve %8,7'si (2/23) AMAÇ: Daptomisinin, rifampisin ve gentamisin ile kombinasyonlarının, hem yüksek düzeyde aminoglikozid direnci (HLAR) olan ve hem de HLAR olmayan (non-HLAR) vankomisine dirençli enterokok (VRE) suşlarına karşı etkinliği in-vitro koşullarda araştırılmıştır. YÖNTEM: Otuz dokuz VRE suşunun laboratuvar tanısı konvansiyonel yöntemler ile yapılmıştır. HLAR araştırması için 120 µg gentamisin ve 300 µg streptomisin içeren diskler kullanılarak yapılan difüzyon yön-temi sonucunda; suşların %41'inin (16/39) gentamisin ve streptomisine yüksek düzeyde dirençli (HLAR) ve %59'unun (23/39) ise duyarlı (non-HLAR) olduğu belirlenmiştir. Çalışmada kullanılan tüm antibiyotiklerin minimum inhibitör konsantrasyon (MİK) değerleri, Clinical and Laboratory Standards

show abstract

Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies

Cited by 88 publications

References 28 publications

Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia

Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia

Altering the Proclivity towards Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus Using Combinations with Other Antibiotics

In-vitro activities of daptomycin in combination with rifampicin and gentamicin against VRE strains.

Contact Info

Product

Resources

About